Jacob Vadakekalam, MD
Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1316904139
Payments from drug & device makers
Across 1,534 payments — averaging $35.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$15K
- Valeritas, Inc.$6K
- Novo Nordisk$5K
- Senseonics, Incorporated$3K
- AstraZeneca$2K
- Medtronic$2K
- plus $21K from 54 others
What the payments were for
- Consulting fees$2,0404%
- Speaking & faculty fees$23,18843%
- Travel & lodging$4761%
- Food & beverage$28,09352%
- Education$910%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- V-GO$5,801
- LYUMJEV$3,663
- Eversense$2,800
- RYBELSUS$2,040
- iLet Bionic Pancreas$1,958
- t:slim X2 insulin pump$1,300
- MINIMED 780G$635
- FARXIGA$587
- t-slim insulin pump$575
- CeQur Simplicity$413
- EVERSENSE E3 SENSOR KIT - RETAIL$282
- TWIIST$266
- DEXCOM CGM$227
- iLet Insulin Infusion Kit Inset$148
- iLet Insulin Infusion Kit Contact Detach$148
- MINIMED 770G$139
- INPEN SMART INSULIN DELIVERY SYSTEM$127
- ZEPBOUND$122
- JARDIANCE$122
- PRALUENT$122
How this compares
$53,946 in reported general payments places this provider in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 367 | $527,655 |
| MounjaroTirzepatide | 304 | $405,483 |
| JardianceEmpagliflozin | 182 | $260,070 |
| FarxigaDapagliflozin Propanediol | 180 | $230,501 |
| TrulicityDulaglutide | 107 | $201,183 |
| AfrezzaInsulin Regular, Human | 43 | $92,691 |
| Humalog Kwikpen U-200Insulin Lispro | 22 | $75,090 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 104 | $62,257 |
| Tresiba Flextouch U-100Insulin Degludec | 58 | $59,707 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $55,617 |
| RybelsusSemaglutide | 25 | $51,159 |
| Bydureon BciseExenatide Microspheres | 16 | $34,890 |
| Repatha SureclickEvolocumab | 26 | $30,967 |
| HumalogInsulin Lispro | 99 | $30,620 |
| Cequr SimplicityBolus Insulin Pump, 200 Unit | 54 | $27,311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev, Insulin Lispro | $14,888 | $658,751601 claims |
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $4,790 | $628,631476 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,561 | $284,062199 claims |
| AstraZenecaFarxiga | $2,500 | $230,501180 claims |
| Mannkind CorporationAfrezza | $1,776 | $92,69143 claims |
| MerckJanuvia, Janumet Xr | $275 | $37,12928 claims |
| Cequr CorporationCequr Simplicity | $542 | $27,31154 claims |
| AbbVieSynthroid | $705 | $11,333133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in San Antonio
- Mark KipnesSan Antonio$10.3M
- Ralph DefronzoSan Antonio$4.8M
- Eugenio CersosimoSan Antonio$4M
- Devjit TripathySan Antonio$1.5M
- Carolina Solis-HerreraSan Antonio$1.3M
- Firas AkhrassSan Antonio$900K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.